The DOI matches its Crossref record; 173 of the 176 references it cites were found in a registry or an index.
Parkinson’s disease: genetics and pathogenesis
Abstract
Recent investigation into the mechanisms of Parkinson's disease (PD) has generated remarkable insight while simultaneously challenging traditional conceptual frameworks. Although the disease remains defined clinically by its cardinal motor manifestations and pathologically by midbrain dopaminergic cell loss in association with Lewy bodies, it is now recognized that PD has substantially more widespread impact, causing a host of nonmotor symptoms and associated pathology in multiple regions throughout the nervous system. Further, the discovery and validation of PD-susceptibility genes contradict the historical view that environmental factors predominate, and blur distinctions between familial and sporadic disease. Genetic advances have also promoted the development of improved animal models, highlighted responsible molecular pathways, and revealed mechanistic overlap with other neurodegenerative disorders. In this review, we synthesize emerging lessons on PD pathogenesis from clinical, pathological, and genetic studies toward a unified concept of the disorder that may accelerate the design and testing of the next generation of PD therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recessively inherited loss-of-function mutations in PTEN-induced kinase 1 (PINK1) and the E3 ubiquitin ligase PRKN are the most common genetic causes for early-onset PD, which occurs in about 5%–10% of cases [1, 2].”
From miRNA family miR-29 inhibits PINK1-PRKN signaling via ATG9A (2026) · cites this paper as [1]
In the citing paper
“Loss-of-function mutations in the genes encoding PINK1 and PRKN result in early-onset Parkinson disease (EOPD).”
From miRNA family miR-29 inhibits PINK1-PRKN signaling via ATG9A (2026) · cites this paper as [1]
In the citing paper
“A complex interplay of genetic and environmental factors is thought to drive the pathogenesis of PD, eventually leading to mitochondrial and autophagic dysfunction (Shulman et al., 2011).”
From Microbiome–microglia connections via the gut–brain axis (2019) · cites this paper as Shulman et al., 2011
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Research works printed but not linked: 4
- Parkinson J, 1817, An Essay on the Shaking Palsy
- Priyadarshi A, 2000, Neurotoxicology, 21, 435
- Gilks W, 2005, Lancet, 365, 415
- Nichols WC, 2005, Lancet, 365, 410
Cited by
Sorted by citations
Items 501–600 of 803
Maor, G., Dubreuil, R. R., & Feany, M. Β. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1922-22.2022 · Cited by 13
Self-citationA Novel Homozygous p.L539F Mutation Identified inPINK1Gene in a Moroccan Patient with Parkinsonism
Haj, R. B. E., Regragui, W., Tazi‐Ahnini, R., Skalli, A., Bouslam, N., Benomar, A., Yahyaoui, M., & Bouhouche, A. (2016) · BioMed Research International · doi:10.1155/2016/3460234 · Cited by 11
Urinary Incontinence, Incident Parkinsonism, and Parkinson’s Disease Pathology in Older Adults
Buchman, N., Leurgans, S. E., Shah, R. J., VanderHorst, V., Wilson, R. S., Bachner, Y. G., Tanné, D., Schneider, J. A., Bennett, D. A., & Buchman, A. S. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw235 · Cited by 11
The association between Parkinson disease and Toxocara infection/exposure: A case-control study
Khatir, A. A., Abbasi, A., Sarandili, S., Sepidarkish, M., Naghibi, A. F., Arjmandi, D., & Rostami, A. (2025) · Journal of Helminthology · doi:10.1017/s0022149x25000161 · Cited by 11
Greenbaum, L., & Lerer, B. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00027 · Cited by 10
Podurgiel, S. J., Spencer, T., Kovner, R., Baqi, Y., Müller, C. E., Correa, M., & Salamone, J. D. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.10.008 · Cited by 10
Harnessing advances in structural MRI to enhance research on Parkinson’s disease
Ziegler, D. A., & Augustinack, J. C. (2013) · Imaging in Medicine · doi:10.2217/iim.13.8 · Cited by 10
Vecchis, R. D., Cantatrione, C., Mazzei, D., Baldi, C., & Maio, M. D. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2541e · Cited by 10
RetractedFernandez-Abascal, J., Chiaino, E., Frosini, M., Davey, G. P., & Valoti, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113955 · Cited by 10
Trzoss, L., Xu, J., Lacoske, M. H., & Theodorakis, E. A. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.126 · Cited by 10
Jiang, Y.-K., Li, M., Wang, S.-Y., Hao, Z., Meng, X., Kuang, H., Yang, B., & Liu, Y. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105883 · Cited by 9
Yang, P., Liu, Y., Tong, Z., Huang, Q., Xie, X., Mao, S.-Y., Ding, J., Lu, M., Tan, R. X., & Hu, G. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01259-y · Cited by 9
Liang, J.-Y., Yuan, X., Jiang, J., Zhang, P., & Kuang-Tan (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115167 · Cited by 13
Targeting NLRP3 Inflammasomes: A Trojan Horse Strategy for Intervention in Neurological Disorders
Tork, M. A. B., Fotouhi, S., Roozi, P., & Negah, S. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04359-2 · Cited by 9
Proceedings: Cell Therapies for Parkinson's Disease From Discovery to Clinic
Canet-Aviles, R., Lomax, G. P., Feigal, E. G., & Priest, C. A. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0146 · Cited by 9
Optimization of EMG movement recognition for use in an upper limb wearable robot
Freer, D., Liu, J., & Yang, G. (2017) · Wearable and Implantable Body Sensor Networks · doi:10.1109/bsn.2017.7936041 · Cited by 9
Hamid, Z., Basit, A., Pontis, S., Piras, F., Assogna, F., Bossù, P., Pontieri, F. E., Stefani, A., Spalletta, G., Franceschi, P., et al. (2019) · Metabolomics · doi:10.1007/s11306-019-1536-z · Cited by 10
Feliciano, J. S., Rodrigues, S. M. A., Lana, R. D. C., & Polese, J. C. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04701-1 · Cited by 9
Yeast Proteins may Reversibly Aggregate like Amphiphilic Molecules
Dasmeh, P., & Wagner, A. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167352 · Cited by 9
Is Disrupted Mitophagy a Central Player to Parkinson’s Disease Pathology?
Ko, T. K., & Tan, D. J. Y. (2023) · Cureus · doi:10.7759/cureus.35458 · Cited by 9
Qi, D., Wang, Q., Li, H., Zhang, T., Lan, R., Kwong, D. W. J., Wong, W., Wong, K., Li, S., & Lu, F. (2015) · Molecular BioSystems · doi:10.1039/c5mb00497g · Cited by 9
Zhang, J., Zeng, H., Zhu, L., Deng, L., Fang, X., Deng, X., Liang, H., Tang, C., Cao, X., Lü, Y., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9595-2 · Cited by 9
Dietary Phytochemicals in Neurodegenerative Disease
Jacquet, A. D. R., Tambe, M. A., & Rochet, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00018-7 · Cited by 8
Role of Paeonol in an Astrocyte Model of Parkinson’s Disease
Ye, M., Yi, Y., Wu, S., Zhou, Y., & Zhao, D. (2017) · Medical Science Monitor · doi:10.12659/msm.906716 · Cited by 9
RetractedKopinathan, A., Scammells, P. J., Lane, J. R., & Capuano, B. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0010 · Cited by 9
Causal Control: A Rationale for Causal SelectionPreprint
Ross, L. N. (2015) · PhilSci-Archive (University of Pittsburgh) · Cited by 9
Animal models of Parkinson’s disease
Le, W., & Jankovic, J. J. (2013) · doi:10.2217/ebo.13.115 · Cited by 9
Role of NLRP3 Inflammasomes in Neurodegenerative Diseases
Demirtaş, N., Mazlumoğlu, B. Ş., & Palabıyık, Ş. S. (2023) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2023.23349 · Cited by 8
Kumar, S., Malviya, R., Sridhar, S. B., Shareef, J., & Wadhwa, T. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100369 · Cited by 8
Platelets and Neurodegenerative Diseases
Donner, L., & Elvers, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-47462-5_81 · Cited by 7
Sofiabadi, M., Rastgoo, N., & Haghdoost-Yazdi, H. (2021) · Biological Trace Element Research · doi:10.1007/s12011-021-03012-6 · Cited by 8
RetractedLockhart, T. E., Frames, C., Olson, M. C., Moon, S. H., Peterson, D., & LIEBERMAN, A. N. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1211441 · Cited by 8
The influence of dopaminergic medication on gait automaticity in Parkinson’s disease
Workman, C. D., & Thrasher, T. A. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.03.007 · Cited by 8
Norepinephrine–Fe(III)–ATP Ternary Complex and Its Relevance to Parkinson’s Disease
Kou, L., Duan, Y., Wang, P., Fu, Y., Darabedian, N., He, Y., Jiang, D., Chen, D., Xiang, J., Liu, G., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00009 · Cited by 8
Jing, S., Wang, Z., Zhang, J., Li, X., & Huang, R. (2021) · Pharmacognosy Magazine · doi:10.4103/pm.pm_291_19 · Cited by 8
The effects of microbiota abundance on symptom severity in Parkinson’s disease: A systematic review
Papić, E., Rački, V., Hero, M., Tomić, Z., Čizmarević, N. S., Kovanda, A., Kapović, M., Hauser, G., Peterlin, B., & Vuletić, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1020172 · Cited by 9
Nutraceuticals Neuroprotect Naturally
Amtul, Z., & Rahman, A. (2016) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63749-9.00011-6 · Cited by 8
Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing α-Synuclein
Noronha, C., Perfeito, R., Laço, M., Wüllner, U., & Rego, A. C. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2199-7 · Cited by 8
Microbubble-facilitated ultrasound pulsation promotes direct α-synuclein gene delivery
Lin, C.-J., Lin, C., Lin, Y., Huang, C.-Y., Wei, K., Chen, J., Lee‐Chen, G., & Liu, H.-L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.017 · Cited by 8
O'Connor, J. L., Fountos, D. M., Firouzan, B., Azizi, F., Ghasemi, R., & Kashfi, K. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00710 · Cited by 8
Stem Cell-Based Approaches in Parkinson's Disease Research
Kim, M. S., Yoon, S., Choi, J., Kim, Y. J., & Lee, G. (2024) · International Journal of Stem Cells · doi:10.15283/ijsc23169 · Cited by 7
Huang, P., Zhu, Z., Li, W., Zhang, R., Chi, Y., & Gong, W. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00775-2 · Cited by 8
α-Synuclein and β-Amyloid form a Bridged Copper Complex
Drew, S. C. (2015) · Applied Magnetic Resonance · doi:10.1007/s00723-015-0662-7 · Cited by 7
Differential interaction of α-synuclein N-terminal segment with mitochondrial model membranes
Vidaurri, E. M., Chávez-Montes, A., Garza-Tapia, M., Castro‐Ríos, R., & González-Horta, A. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.08.049 · Cited by 7
A role of human microbiota in the development of neurodegenerative diseases
Epishina, I. V., & Budanova, E. V. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202212210157 · Cited by 8
Diagnosis and Differential Diagnosis of Parkinson’s Disease
Lingor, P., Liman, J., Kallenberg, K., Sahlmann, C., & Bähr, M. (2011) · InTech eBooks · doi:10.5772/18987 · Cited by 7
pTSara-NatB, an improved N-terminal acetylation system for recombinant protein expression in E. coli
Rovere, M., Powers, A. E., Patel, D. S., & Bartels, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198715 · Cited by 7
Bonifácio, M. J., Sousa, F., & Soares-da-Silva, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173742 · Cited by 7
Cell type-specific transcriptome profiling in mammalian brains
Cui, F. (2016) · Frontiers in bioscience · doi:10.2741/4434 · Cited by 7
The Coming Epidemic of Neurologic Disorders: What Science Is – and Should Be – Doing About It
Petsko, G. A. (2012) · Daedalus · doi:10.1162/daed_a_00165 · Cited by 7
Lignan Diesters of Canangafruticoside A from the Leaves of Cananga odorata var. odorata
Haruka, K., Sugimoto, S., Matsunami, K., Otsuka, H., & Lhieochaiphant, S. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00611 · Cited by 7
miRNA family miR-29 inhibits PINK1-PRKN dependent mitophagy via ATG9APreprint
Markham, B. N., Ramnarine, C., Kim, S., Grever, W. E., Soto‐Beasley, A. I., Heckman, M. G., Ren, Y., Osborne, A. C., Bhagwate, A. V., Liu, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.17.576122 · Cited by 7
Xu, H., Zhang, L., Luo, Y.-Y., Wang, L., Zhang, Y.-P., Chen, P.-Q., Ba, X.-Y., Han, J. Z., & Luo, H. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.958 · Cited by 6
Parkinson’s Disease and Parkin: Insights from Park2 Knockout Mice
Stephenson, S. E. M., Juliet, M., & Paul, J. (2012) · InTech eBooks · doi:10.5772/18148 · Cited by 6
A Comprehensive Study of miRNAs in Parkinson’s Disease: Diagnostics and Therapeutic Approaches
Siddique, Y. H., & Owais, S. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220111152756 · Cited by 6
Cognition and Quality of Life in Parkinson's Disease
Kalaba, Ö., & Güzeloğlu, Ö. M. C. (2024) · Psikiyatride Guncel Yaklasimlar · doi:10.18863/pgy.1374234 · Cited by 5
The role of autophagy in brain health and disease: Insights into exosome and autophagy interactions
Wang, H., Lv, C., Feng, L., Guo, J., Zhao, S., & Jiang, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38959 · Cited by 7
Current Insights on Neurodegeneration by the Italian Proteomics Community
Alberio, T., Brughera, M., & Lualdi, M. (2022) · Biomedicines · doi:10.3390/biomedicines10092297 · Cited by 6
Are static posturography-assisted biofeedback exercises effective in Parkinson's disease?
Yakşi, E., Yaşar, M. F., Türel, C. A., & Balcı, M. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0042-1755325 · Cited by 6
NECAB2 is an endosomal protein important for striatal function
Bueno, D., Dey, P. N., Schacht, T., Wolf, C., Wüllner, V., Morpurgo, E., Rojas-Charry, L., Sessinghaus, L., Leukel, P., Sommer, C., et al. (2023) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2023.09.003 · Cited by 6
Dai, Y., Wu, Y., & Li, Y. (2015) · PubMed Central · Cited by 6
Sjögren, M. J. C., Huttunen, H. J., Svenningsson, P., & Widner, H. (2021) · Genes · doi:10.3390/genes12101529 · Cited by 6
Matynia, A., Recio, B. S., Myers, Z., Parikh, S., Goit, R. K., Brecha, N. C., & Müller, L. P. D. S. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.1.28 · Cited by 6
Marmosets in Neurologic Disease Research
Philippens, I. H. C. H. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811829-0.00023-6 · Cited by 5
Hui, C., Jin, J., Ji, M., Wang, H., Wang, X., Ma, J., Wang, Y., Si, Y., Chen, S., & Guo, T. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01397-6 · Cited by 5
Donev, R., & Howell, O. W. (2012) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-394287-6.00004-5 · Cited by 5
Molecular Pathology of the Central Nervous System
Harris, B. T., & Hattab, E. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4900-3_16 · Cited by 5
Mucksavage, J. J., & Kim, K. S. (2020) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000306 · Cited by 5
Shahidani, S., Rajaei, Z., Alaei, H., & Mohammadzadeh, S. (2022) · Physiology and Pharmacology · doi:10.52547/phypha.26.1.6 · Cited by 5
Chiu, T., Huang, H., Chang, H., Wu, H.-R., & Wang, M.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032017 · Cited by 5
Gut microbiota and psychiatric disorders
Jaiswal, S., Bag, A., & Bhandarı, S. S. (2022) · Open Journal of Psychiatry & Allied Sciences · doi:10.5958/2394-2061.2022.00016.7 · Cited by 4
Buchman, A. S., Yu, L., Oveisgharan, S., Zammit, A. R., Wang, T., Shulman, J. M., VanderHorst, V., Nag, S., & Bennett, D. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240593 · Cited by 6
Self-citationCyanotoxins: from poisoning to healing –a possible pathway?
Dias, E. M., Paulino, S., & Pereira, P. (2015) · Limnetica · doi:10.23818/limn.34.13 · Cited by 5
Minakawa, E. N., Yamakado, H., Tanaka, A., Uemura, K., Takeda, S., & Takahashi, R. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.09.006 · Cited by 5
New Magnetic Resonance Imaging Biomarkers Advance the Characterisation of Parkinson’s Disease
Ziegler, D. A., & Corkin, S. (2013) · European Neurological Review · doi:10.17925/enr.2013.08.02.85 · Cited by 5
Visualization of Decision Tree State for the Classification of Parkinson's Disease
Williams, D., Mudali, D., Buddelmeijer, H., Noorishad, P., Meles, S. K., Renken, R. J., Leenders, N., Valentijn, E. A., & Roerdink, J. B. T. M. (2016) · Journal of Biomedical Engineering and Medical Imaging · doi:10.14738/jbemi.33.1858 · Cited by 5
dos Santos, D. M. P., Neto, M. F., Lemos, M. R., da Silva, V. J., Federal, W. A. D. S., & de Lucena, V. F. (2019) · International Conference on Consumer Electronics · doi:10.1109/icce-berlin47944.2019.8966237 · Cited by 5
Role of Genes and Treatments for Parkinson’s Disease
Naz, F., & Siddique, Y. H. (2020) · The Open Biology Journal · doi:10.2174/1874196702008010047 · Cited by 5
Jankovic, J. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0434-1.00096-7 · Cited by 5
Xu, M., Zhang, S., Zhao, H., Ma, C., & Pan, Y. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1617730 · Cited by 5
RetractedWang, W., Song, N., Jia, F., Xie, J., Zhang, Q., & Jiang, H. F. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.01.33 · Cited by 5
Wąsik, A., Romańska, I., Zelek-Molik, A., Nalepa, I., & Antkiewicz‐Michaluk, L. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9939-6 · Cited by 5
Garip, A., Stefanova, D., & Tzankova, V. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e175265 · Cited by 5
NECAB family of neuronal calcium-binding proteins in health and disease
Bueno, D., Schäfer, M. K. E., Wang, S., Schmeißer, M. J., & Methner, A. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00094 · Cited by 5
An Overview of Neurodegenerative Disorders
Mittal, P., & Agrawal, N. (2024) · Springer eBooks · doi:10.1007/978-981-97-4288-2_1 · Cited by 4
Microbial diversity in drug-naïve Parkinson’s disease patients
Papić, E., Rački, V., Hero, M., Zimani, A. N., Sajko, M. Č., Rožmarić, G., Čizmarević, N. S., Ostojić, S., Kapović, M., Hauser, G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328761 · Cited by 6
Samadi, A. K. (2014) · Journal of Ancient Diseases & Preventive Remedies · doi:10.4172/2329-8731.1000e113 · Cited by 4
Hami, J., Hosseini, M., Vafaei‐Nezhad, S., Shahi, S., Lotfi, N., Ehsani, H., & Sadeghi, A. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.187374 · Cited by 4
Stem Cell Therapy for Parkinson’s Disease: A Review
Gandhi, V., Burle, S. S., & Kosalge, S. B. (2018) · Pharmatutor · doi:10.29161/pt.v6.i6.2018.1 · Cited by 4
Unleashing the shape of l -DOPA at last
Sanz‐Novo, M., León, Í., Alonso, E. R., & Alonso, J. L. (2021) · Physical Chemistry Chemical Physics · doi:10.1039/d1cp05066d · Cited by 4
Zhang, L., Shen, X. X., Chu, C., Liu, S., Wang, J., Wang, Y., Zhang, J., Cao, T., Wang, F., Zhu, X., et al. (2024) · Cognitive Neurodynamics · doi:10.1007/s11571-023-10016-6 · Cited by 4
Bernal-Conde, L. D., Peña-Martínez, V., Torres, C. A. M., Ramos-Acevedo, R., Arias-Carrión, Ó., Padilla-Godínez, F. J., Delgado-González, A., Palomero‐Rivero, M., Collazo-Navarrete, O., Soto-Rojas, L. O., et al. (2024) · Life · doi:10.3390/life14060728 · Cited by 7
Wang, Q.-L., Gu, X., Yang, L., Jiang, Y., Zhang, J., & He, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1417515 · Cited by 4
van den Hoff, J., & Thalmann, S. (2020) · The Open Biology Journal · doi:10.2174/1874196702008010001 · Cited by 4
Rahul, R., & Siddique, Y. H. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210903101841 · Cited by 5
Parkinson’s disease hospitalization rates and pesticide use in urban and non-urban regions of Brazil
Santos, A. D. S. E., Krawczyk, N., Parks, C. G., Asmus, C. I. R. F., Câmara, V. D. M., Lima, J., & Meyer, A. (2021) · Cadernos Saúde Coletiva · doi:10.1590/1414-462x202129040236 · Cited by 4
Mohamed, W. M. Y. (2023) · PubMed Central · Cited by 4
Tekin, I., Carkaci‐Salli, N., Lewis, M. M., Mailman, R. B., Huang, X., & Vrana, K. E. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.12.015 · Cited by 4
Kitajima, T., Mizote, S., Bonifácio, M. J., Umemura, T., Yoneda, K., Moser, P. C., Soares-da-Silva, P., & Tanaka, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.10.001 · Cited by 4
A New Cell Model for Investigating Prion Strain Selection and Adaptation
Philiastides, A., Ribes, J. M., Yip, D. C.-M., Schmidt, C., Benilova, I., & Klöhn, P. (2019) · Viruses · doi:10.3390/v11100888 · Cited by 5
Metadata
- Authors
- Shulman, J. M., De Jager, P. L., & Feany, M. B.
- Affiliations
- Broad Institute (US)
- Departments of Neurology, Boston, Massachusetts 02115;
- Departments of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115;
- ORCID
- Shulman, Joshua M.
- Venue
- Annual Review of Pathology: Mechanisms of Disease
- Publisher
- Annual Reviews
- Published
- 2011-02-28
- Volume
- 6
- Issue
- 1
- Pages
- 193-222
- ISSN
- 1553-4006 (ISSN-L)
- 1553-4014
- OpenAlex
- W2129917779
- Cited by
- 801
- References
- 176
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 42 · 2023: 34 · 2022: 64 · 2021: 64 · 2020: 46 · 2019: 59 · 2018: 54 · 2017: 59 · 2016: 74 · 2015: 64 · 2014: 56 · 2013: 65 · 2012: 52
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annual Review of Pathology Mechanisms of Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, susceptibility genes, pathogenesis, dopaminergic neuron loss, Lewy bodies, non-motor symptoms, animal models, neurodegeneration, molecular pathways
- MeSH terms
- Animals, Humans, Parkinson Disease, Lewy Bodies, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
